Dabur India expects mid-single digit revenue growth in Q4
International Business is expected to register double-digit growth in constant currency terms
International Business is expected to register double-digit growth in constant currency terms
Combination will create a Canadian Health Champion spanning generic, biosimilar and branded pharmaceuticals
Application based on results from the TROPION-Breast01 Phase III trial
If approved, enfortumab vedotin with KEYTRUDA would be the first combination in China to offer an alternative to chemotherapy
Executes the first project for developing and manufacturing a novel anticancer mAb
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
This partnership combines Tata Elxsi's design and technology expertise along with Dräger's expertise in medical and safety technology
The facility will manufacture tablets, capsules, and injections for the oncology segment
Subscribe To Our Newsletter & Stay Updated